Simcere Pharmaceutical Group Secures Full Approval for Cosela in China
Simcere Pharmaceutical Group (HKG: 2096), a leading pharmaceutical company based in China, has announced that...
Novartis Announces Positive Interim Results for Atrasentan in IgA Nephropathy Phase III Study
Novartis (NYSE: NVS), a global healthcare company, has released interim results from an ongoing Phase...
BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...
Novartis Seeks Access to Takeda’s Business Records Over Confidentiality Concerns
Swiss pharmaceutical giant Novartis (NYSE: NVS) filed a complaint with a US court last week,...
Roche’s Vabysmo Receives FDA Approval for Macular Edema Treatment Following RVO
Swiss pharmaceutical giant Roche (SWX: ROG) announced last week that it has received an indication...
AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues
AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year...
Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year
India-based generics giant Dr. Reddy’s Laboratories Ltd (NYSE: RDY) has released its financial report for...
Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer based in...
Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial
Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...
China Grand Pharma’s Lava Liquid Embolic Agent Officially Commercialized in the US
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization...
Mindray Bio-Medical Electronics Posts Strong Q1-Q3 2023 Financial Results
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has revealed a robust financial performance for...
Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...
Innovent Biologics’ Mazdutide Shows Promising Weight Loss Results in Phase II Trial
China-based Innovent Biologics Inc., (HKG: 1801) has revealed compelling Phase II data for its weight...
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a...
Junshi Biosciences’ PD-1 Inhibitor Loqtorzi Approved by FDA for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the US...
TG ImmunoPharma’s Bispecific Antibody TGI-6 Approved for Phase I Clinical Study by NMPA
China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the National...
Everest Medicines’ Nefecon Receives First Regional NDA Approval in Macau for IgAN Treatment
China-based Everest Medicines (HKG: 1952) has announced that its New Drug Application (NDA) for Nefecon,...
Wyze Biotech’s RJMty19 Injection Accepted for CDE Review for r/r B-Cell NHL
Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has announced...
Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has released its financial...
Shanghai Henlius Biotech and Intas Pharmaceuticals Ink New Licensing Deal for PD-1 mAb
China’s Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new licensing agreement with India-based...